CR20120448A - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
CR20120448A
CR20120448A CR20120448A CR20120448A CR20120448A CR 20120448 A CR20120448 A CR 20120448A CR 20120448 A CR20120448 A CR 20120448A CR 20120448 A CR20120448 A CR 20120448A CR 20120448 A CR20120448 A CR 20120448A
Authority
CR
Costa Rica
Prior art keywords
heterocyclic compound
compound
cancer
salt
useful
Prior art date
Application number
CR20120448A
Other languages
English (en)
Inventor
Misaki Homma
Toru Miyazaki
Yuya Oguro
Osamu Kurasawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120448(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20120448A publication Critical patent/CR20120448A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto útil como un agente profiláctico o terapéutico para cáncer. Se describe especificamente un compuesto representado por la fórmula (I) en donde cada símbolo es como se define en la descripción o una sal del mismo, o un promedicamento del compuesto o la sal del mismo, el cual es útil para la prevención o tratamiento de cáncer.
CR20120448A 2010-02-17 2012-08-29 Compuesto heterocíclico CR20120448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010031899 2010-02-17
JP2010131950 2010-06-09

Publications (1)

Publication Number Publication Date
CR20120448A true CR20120448A (es) 2012-11-13

Family

ID=44482985

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120448A CR20120448A (es) 2010-02-17 2012-08-29 Compuesto heterocíclico

Country Status (37)

Country Link
US (6) US8722660B2 (es)
EP (2) EP3533797B1 (es)
JP (1) JP5689454B2 (es)
KR (1) KR101735868B1 (es)
CN (1) CN102844320B (es)
AU (1) AU2011216404B2 (es)
BR (1) BR112012020311B1 (es)
CA (1) CA2790284C (es)
CL (1) CL2012002250A1 (es)
CO (1) CO6592104A2 (es)
CR (1) CR20120448A (es)
CY (1) CY1121792T1 (es)
DK (1) DK2540728T3 (es)
DO (1) DOP2012000224A (es)
EA (1) EA020724B1 (es)
EC (1) ECSP12012160A (es)
ES (1) ES2733221T3 (es)
GE (1) GEP20146202B (es)
HR (1) HRP20190947T1 (es)
HU (1) HUE043514T2 (es)
IL (1) IL221442A0 (es)
LT (1) LT2540728T (es)
MA (1) MA34064B1 (es)
ME (1) ME03410B (es)
MX (1) MX353500B (es)
MY (1) MY164776A (es)
NZ (1) NZ602089A (es)
PE (1) PE20130184A1 (es)
PH (1) PH12012501650B1 (es)
PL (1) PL2540728T3 (es)
PT (1) PT2540728T (es)
RS (1) RS58796B1 (es)
SG (1) SG183304A1 (es)
SI (1) SI2540728T1 (es)
SM (1) SMT201900385T1 (es)
TN (1) TN2012000401A1 (es)
WO (1) WO2011102399A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34797B1 (fr) * 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
JP6569908B2 (ja) 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
TW201620879A (zh) 2014-04-28 2016-06-16 杜邦股份有限公司 除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) * 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
CA3007840C (en) 2015-12-07 2020-09-15 Zymergen Inc. Microbial strain improvement by a htp genomic engineering platform
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
PL3436463T3 (pl) * 2016-03-28 2021-11-08 Takeda Pharmaceutical Company Limited Postaci krystaliczne półwodzianu 2-[(2s)-1-azabicyklo[2.2.2]okt-2-ylo]-6-(3-metylo-1h-pirazol-4-ilo)tieno[3,2-d]pirymidyn-4(3h)-onu
EA035560B1 (ru) * 2016-07-28 2020-07-07 Такеда Фармасьютикал Компани Лимитед Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
WO2018087527A1 (en) 2016-11-08 2018-05-17 Cancer Research Technology Limited Pyrimidinone derivatives as cdc7 inhibitors
EP3589747B1 (en) 2017-03-01 2021-05-19 Takeda Pharmaceutical Company Limited Method of predicting effects of cdc7 inhibitor
CN110381950B (zh) * 2017-05-21 2020-09-04 南京正济医药研究有限公司 作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN111989331B (zh) * 2018-04-02 2024-04-12 武田药品工业株式会社 2-[(2S)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1H-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3H)-酮的合成方法
TWI846703B (zh) 2018-06-19 2024-07-01 日商武田藥品工業股份有限公司 癌症治療方法
CA3106557A1 (en) * 2018-07-19 2020-01-23 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor
JP7579781B2 (ja) 2018-09-24 2024-11-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｃｄｃ７阻害剤を含む癌の治療方法
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3978501A4 (en) * 2019-05-30 2023-05-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TETRACYCLIC COMPOUNDS AS CDC7 INHIBITORS
BR112022000734A2 (pt) * 2019-07-19 2022-04-12 Takeda Pharmaceuticals Co Método para tratar câncer em um paciente, uso de composto 1, e, composto 1
JP2022546294A (ja) * 2019-08-20 2022-11-04 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｃｄｃ７阻害剤として使用される四環式化合物
EP4069369A4 (en) * 2019-12-06 2024-02-14 Schrödinger, Inc. CYCLIC COMPOUNDS AND METHODS OF USE
JP2023541047A (ja) * 2020-09-10 2023-09-27 シュレーディンガー， インコーポレイテッド がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
KR20230116005A (ko) * 2020-11-30 2023-08-03 치아타이 티안큉 파마수티컬 그룹 주식회사 Cdc7 억제제로 사용되는 염 형태 및 이의 결정 형태
CN112661770B (zh) * 2020-12-24 2022-11-08 南京正济医药研究有限公司 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
JP2024506314A (ja) * 2021-02-08 2024-02-13 武田薬品工業株式会社 がん治療のための併用療法
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法
TW202330552A (zh) * 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
WO2025160538A1 (en) * 2024-01-26 2025-07-31 The Board Of Regents Of The University Of Texas System Compositions and methods for treating hair graying and loss associated with aging
WO2025168620A1 (en) 2024-02-07 2025-08-14 Bayer Aktiengesellschaft Heteroaryl-substituted 4,5-dihydro-1h-2,4,5-oxadiazines as novel fungicides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
EP1329454A1 (en) 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
AU2004247470B2 (en) * 2003-06-11 2009-04-23 Xention Limited Thienopyrimidine derivatives as potassium channel inhibitors
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
DE602004014163D1 (de) * 2003-08-08 2008-07-10 Pfizer Italia Srl Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
JP4761389B2 (ja) 2004-04-09 2011-08-31 株式会社ジーンケア研究所 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
EP1856128A4 (en) 2005-01-19 2009-12-23 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
WO2007011284A1 (en) 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
EP1932841B1 (en) 2005-08-30 2014-01-01 Asahi Kasei Pharma Corporation Sulfonamide compound
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) * 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
US20090030196A1 (en) 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
CL2008000252A1 (es) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
WO2009112490A1 (en) 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides as zap-70 inhibitors
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2009158620A2 (en) 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis methods of use thereof
EP2403857B1 (en) 2009-03-05 2013-12-04 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
JP2013504531A (ja) 2009-09-11 2013-02-07 バイエル・ファルマ・アクチェンゲゼルシャフト 抗癌薬としての置換（ヘテロアリールメチル）チオヒダントイン
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids

Also Published As

Publication number Publication date
PT2540728T (pt) 2019-07-11
EA020724B1 (ru) 2015-01-30
CA2790284C (en) 2019-01-08
US8921354B2 (en) 2014-12-30
AU2011216404A1 (en) 2012-09-20
US8722660B2 (en) 2014-05-13
US9655900B2 (en) 2017-05-23
KR20130001246A (ko) 2013-01-03
CN102844320A (zh) 2012-12-26
CY1121792T1 (el) 2020-07-31
RS58796B1 (sr) 2019-07-31
EP3533797A1 (en) 2019-09-04
ES2733221T3 (es) 2019-11-28
DK2540728T3 (da) 2019-05-13
EP3533797B1 (en) 2023-12-20
MY164776A (en) 2018-01-30
PH12012501650B1 (en) 2018-11-07
IL221442A0 (en) 2012-10-31
HRP20190947T1 (hr) 2019-07-26
US20140228352A1 (en) 2014-08-14
US20140235615A1 (en) 2014-08-21
TN2012000401A1 (en) 2014-01-30
US20160310494A1 (en) 2016-10-27
US20170209452A1 (en) 2017-07-27
MA34064B1 (fr) 2013-03-05
CN102844320B (zh) 2016-03-23
PE20130184A1 (es) 2013-03-09
EA201290800A1 (ru) 2013-03-29
SI2540728T1 (sl) 2019-06-28
DOP2012000224A (es) 2013-01-31
US9388195B2 (en) 2016-07-12
EP2540728A1 (en) 2013-01-02
CA2790284A1 (en) 2011-08-25
LT2540728T (lt) 2019-06-25
CO6592104A2 (es) 2013-01-02
EP2540728A4 (en) 2013-11-06
AU2011216404B2 (en) 2016-04-07
BR112012020311B1 (pt) 2019-01-29
MX2012009602A (es) 2012-12-17
KR101735868B1 (ko) 2017-05-15
US20130029969A1 (en) 2013-01-31
ME03410B (me) 2020-01-20
PH12012501650A1 (en) 2012-10-22
EP2540728B1 (en) 2019-04-10
US20150158882A1 (en) 2015-06-11
BR112012020311A2 (pt) 2017-03-01
GEP20146202B (en) 2014-11-25
SMT201900385T1 (it) 2019-09-09
NZ602089A (en) 2014-05-30
US8933069B2 (en) 2015-01-13
CL2012002250A1 (es) 2013-02-08
SG183304A1 (en) 2012-09-27
WO2011102399A1 (ja) 2011-08-25
JPWO2011102399A1 (ja) 2013-06-17
ECSP12012160A (es) 2013-03-28
PL2540728T3 (pl) 2019-09-30
JP5689454B2 (ja) 2015-03-25
MX353500B (es) 2018-01-16
HUE043514T2 (hu) 2019-08-28

Similar Documents

Publication Publication Date Title
ECSP12012160A (es) Compuesto heterociclico
MX2013006113A (es) Compuestos biciclico.
EA201400178A1 (ru) Лечение рака молочной железы
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
MX373786B (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer.
EA201171367A1 (ru) Винилиндазолильные соединения
SI3725810T1 (sl) Kombinacijska terapija, ki vključuje protitelesa proti klavdinu 18.2 za zdravljenje raka
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX368392B (es) Compuesto heterociclico fusionado.
ECSP10010526A (es) Compuesto heterociclico
CR20140537A (es) Compuesto heterocíclico nitrogenado
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX361499B (es) Baricitinib deuterado.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201591024A1 (ru) Димерные соединения
PH12015500399A1 (en) Azaindolines
EA201491581A1 (ru) Везикулярные композиции
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MX2015012043A (es) Agonistas muscarinicos.
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
NZ715554A (en) Method of treating hypertrophic cardiomyopathy